Vertex Pharmaceuticals Inc
NASDAQ: VRTX
$499.88
+$27.08 (+5.7%)
Closing Price on November 5, 2024
VRTX Articles
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Monday's top analyst upgrades and downgrades included Apple, BP, CrowdStrike, Delta Air Lines, Moody's, NuStar Energy, PPL, Salesforce.com, Slack Technologies and Wells Fargo.
Published:
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic selling...
Published:
Thursday's top analyst upgrades and downgrades included Alkermes, Amazon.com, Citigroup, eBay, Fastly, Groupon, Lyft, Netflix, ONEOK, Roku, Uber Technologies and Zoom Video Communications.
Published:
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
These five high-conviction health care stock picks from the analysts at Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well the rest of 2020...
Published:
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Jefferies analysts have named 10 companies they think have a solid chance of posting second-quarter results that exceed current Wall Street consensus estimates.
Published:
About nine in 10 CEOs at S&P 500 companies are white men. There are only four female chief executives of color among them.
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
Published: